CD47

Cluster of Differentiation 47; MER6; OA3

CD47 is a glycoprotein that was first identified in 1990 as a protein that associates with integrins, hence its original name integrin-associated protein. CD47 interacts with SIRPα (CD172a or SHPS-1) and its family member SIRPγ, CD47 also interacts with integrins and secreted glycoprotein extracellular matrix protein thrombospondin-1 (TSP-1). Signaling through the CD47/SIRPα axis plays a role in various homeostatic processes, such as maintenance of erythrocytes, innate immune cells and T cells. Moreover, cancer cells and virus-infected and bacteria-infected cells can upregulate CD47 protein expression to prevent immune-mediated elimination.

CD47 Related Products (47):

By Effects:	Inhibitors (36) Activators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P990555

BI-765063	Inhibitor
BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-115983

DMUP	Inhibitor	98.0%
DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity.

HY-P10420

RS17	Inhibitor	99.82%
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.

HY-P99950

Evorpacept	Inhibitor	99.75%
Evorpacept is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region.

HY-P990707

Maplirpacept
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47.

HY-P991027

Spevatamig		≥99.0%
HY-P991027 is an CD47/CLDN18-targeting (H-γ1_L-κ)_(H-γ1_L-κ) type bispecific antibody.

HY-P991023

Safimestomig		≥99.0%
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P99903

Simridarlimab	Inhibitor
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro.

HY-151132

Glutaminyl cyclases-IN-1	Inhibitor	98.21%
Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC₅₀ values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages.

HY-143224

NCGC00138783	Inhibitor
NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis.

HY-P990723

Timdarpacept	Inhibitor	99.95%
Timdarpacept (DNL310) is a recombinant SIRPa-Fc fusion protein that can activate macrophages to enhance anti-tumor activity by blocking CD47-SIRPa.

HY-P991062

Gentulizumab	Inhibitor
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990899

Amostomig
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096).

HY-P991004

Itanistomig
HY-P991004 is an CD274/CD47-targeting (VH-G1CH1-h)-H-γ1_L-κ-L-κ type bispecific antibody.

HY-P990954

Amulirafusp alfa
HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991016

Peluntamig
HY-P991016 is an CD47/DLL3-targeting H-γ1_L-κ type bispecific antibody.

HY-P3968

Thrombospondin-1 (1016-1021) (human, bovine, mouse)
Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity.

HY-P11205

Cys-PKHB1	Activator
Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca⁺ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.

HY-P10813

ZLIRTLHEWY	Inhibitor
ZLIRTLHEWY is a potent peptide CD47/SIRPα interaction inhibitor. ZLIRTLHEWY is promising for research of cancers.

HY-143224A

NCGC00138783 free base	Inhibitor
NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis.

Name
Email *

	Sorry, but the email address you supplied was invalid.